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Purpose
In Suriname, a South American country with 500.000
inhabitants and an estimated prevalence of HIV infec-
tion of 4%, virological monitoring of combination antire-
troviral therapy (cART) is uncommon. Therefore, the
virological response to cART is poorly known. The
objective of this study is to determine the virological
response and to identify risk factors for virological fail-
ure among HIV-infected patients in Suriname. An addi-
tional aim is to develop and validate a prediction model
that could be used to identify patients at risk for virolo-
gical failure.
Methods
100 HIV-infected individuals, treated with cART partici-
pated in this study. Patients were selected from 2 major
hospitals and 4 general medicine practices in Paramar-
ibo, Suriname. Patients were eligible for this study if
they were prescribed cART for 6 months or more, their
last drug pick-up date was no longer than 9 months
before inclusion and if they were at least 18 years old.
To assess risk factors multiple questionnaires were con-
ducted considering HIV stigma (HIV Stigma scale),
Social Support (based on the Norbeck Social Support
Questionnaire), Depression (CES-D scale), Quality of life
(based on the HIV questionnaire of the Medical Out-
comes Study) and Beliefs about Medications (Beliefs
about Medication Questionnaire). In addition, HIV RNA
concentrations were measured in dried blood spots. A
detectable viral load (HIV RNA > 300 copies/mm
3)w a s
considered as virological failure.
Results
19% of all participants had a detectable viral load (range
463-319815). A significant correlation was found
between virological failure and a lower level of social
support (r = -0.0357, p = 0.00), younger age (r = -0.245,
p = 0.014), and higher perceived personalized HIV
stigma (r = 0.206, p = 0.039). A prediction model was
formed consisting of three variables: age, social support
and personalized HIV stigma. This model has a discri-
minatory power of 0.7993 (receiver operating character-
istic) and an explained variance of 0.252 (R
2).
Conclusions
In this Surinamese cohort, 19% of patients treated with
cART are demonstrating virological failure. A prediction
model consisting of age, social support en personalized
stigma scales can predict for almost 80% whether a viral
load will be detectable or not. This prediction model
could assist in identifying patients at risk for virological
failure, especially in situations where virological moni-
toring is unavailable.
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